Tamarly Lists · Thursday · Life sciences investment

6 trends in life sciences investment this week

From 5 November 2026 to 11 November 2026, 18 biotech and health care companies reported $305.3 million of new private money in SEC Form D filings (company count down 23% on the 4-week average of 23.3), and companies registered 50 new trials, 17 of them at Phase 3.

As of . Research from public records, not investment advice.

  1. Venture money into biotech and health care: 18 operating companies reported Form D sales, $305.3 million in total. Companies down 23% on the 4-week average of 23.3; money up 95% on the 4-week average of $156.4 million.
    Source: SEC Form D
  2. Largest biotech or health care raise: Zai Lab Ltd sold $249.9 million. Biotechnology, Form D filed 9 November 2026.
    Source: SEC Form D
  3. New company-sponsored trials: 50 registered. Down 9% on the 4-week average of 54.8.
  4. New company-sponsored Phase 3 trials: 17 registered. Down 17% on the 4-week average of 20.5.
  5. Medicines stepping up a phase: 1 medicines entered a higher trial phase. Tuesday's list has the 12 largest.
  6. Disease with the most new company trials: Obesity, 4 new trials.

How this list is made

Each line compares the 7 days to yesterday with the average of the 4 weeks before; a line is left out while its source has no record for the week yet. Raises are SEC Form D sales by operating biotech, pharmaceutical and health care companies (funds and vehicles left out). Trials are registrations on ClinicalTrials.gov; approvals, clearances and warning letters come from FDA records.

Sources: SEC EDGAR, Form D, ClinicalTrials.gov, FDA.

Get the free weekly round-up every MondayEvery Monday: the week's private raises, IPO filings and deals filed with the SEC, each with its filing, and the most covered news about those companies. No account needed.

See the latest edition